Techspec schreef op 24 augustus 2018 15:01:
Cin/Ruc/Hae hebben allemaal een A-rating betekend: SUPERIEUR
lana P/1 betekend Promising but inconclusive/ belovend maar niet eenduidig
Without long-term safety data
available, we rated the evidence for lanadelumab as promising but inconclusive (“P/I”)
There are significant uncertainties about the long-term safety and efficacy of lanadelumab, a monoclonal antibody inhibiting plasma kallikrein that has the potential to affect angiogenesis, for example, compared with C1-INHs, which replace a physiologic deficiency. New biologic therapies frequently are found to have safety concerns in the years after they are introduced that were not detected in pre-approval